WeVote
Log In

Bill

Bill

A 3611

Relates to including a representative of the drug or medical device manufacturer industry on the state board of pharmacy

2025 Regular Session Introduced by Billy Jones

Bill A 3611 aimed to add a drug or medical device manufacturer representative to the state pharmacy board, influencing regulations and industry representation.

ENACTING CLAUSE STRICKEN
0
WeVote Research Nonpartisan
Bill Summary · A 3611

Summary of Bill A 3611

Bill Overview

  • Bill Number: A 3611
  • Title: Relates to including a representative of the drug or medical device manufacturer industry on the state board of pharmacy
  • Status: Enacting clause stricken
  • Introduced: January 29, 2025
  • Classification: Bill

Purpose and Intent

Bill A 3611 aimed to amend the composition of the state board of pharmacy by including a representative from the drug or medical device manufacturer industry. The intent behind this inclusion was to ensure that the board has insights and perspectives from the pharmaceutical and medical device sectors, potentially enhancing the board's decision-making processes regarding regulations and policies that impact these industries.

Key Provisions

  • Inclusion of Industry Representative: The bill proposed to add one member to the state board of pharmacy who would represent the interests of drug and medical device manufacturers.
  • Board Composition Changes: This change would alter the existing structure of the board, which traditionally consists of members with backgrounds in pharmacy practice, academia, and public health, thereby introducing a new perspective from the manufacturing side of the industry.

Impact

  • Affected Parties:
    • State Board of Pharmacy: The board would see a change in its composition, which could influence its regulatory decisions.
    • Pharmaceutical and Medical Device Manufacturers: These industries would have direct representation, potentially allowing for more favorable regulatory conditions and considerations.
    • Public Health and Safety: The inclusion of a manufacturer representative could lead to discussions that balance industry interests with public health concerns, although it may also raise questions about conflicts of interest.

Legislative Actions

  • January 29, 2025: The bill was introduced and referred to the Higher Education committee for consideration.
  • September 8, 2025: The enacting clause was stricken, effectively halting the bill's progress and indicating that it would not advance to become law.

Related Bills

Bill A 3611 is related to several prior-session bills, including:
- A 7212
- A 3047
- A 1329
- A 2484

These related bills may have addressed similar issues regarding the composition of regulatory boards or the relationship between the pharmaceutical industry and state regulatory bodies.

Conclusion

While Bill A 3611 sought to introduce a significant change to the state board of pharmacy by adding a representative from the drug and medical device manufacturing industry, its progress was halted with the striking of the enacting clause. The implications of such a change, had it been enacted, would have been noteworthy for both the industry and public health sectors.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.